Evidence map›Paper›PMID 27837339›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

HER2 mRNA transcript quantitation in breast cancer.

K Meehan, B Clynick, B Mirzai, P Maslen, J M Harvey, W N Erber

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Classification of Widely and Rarely Expressed Genes with Recurrent Neural Network.Computational and structural biotechnology journal · 2019
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

K MeehanSchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia. katie.meehan@uwa.edu.au.ORCID http://orcid.org/0000-0002-9179-4592
B ClynickSchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia.
B MirzaiSchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia.
P MaslenSchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia.
J M HarveySchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia.
W N ErberSchool of Pathology and Laboratory Medicine (M504), University of Western Australia, Crawley, WA, 6009, Australia.
The University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe human epidermal growth factor receptor 2 (HER2) status in breast cancer is important for prognostic prediction and the determination of optimal treatment. Current methods rely on protein expression, as determined by immunohistochemistry (IHC), as well as gene amplification as determined by in situ hybridisation (ISH). We explored whether quantitative droplet digital PCR (ddPCR) can be used for the detection and absolute quantitation of HER2 mRNA.

methodsDigital droplet PCR (ddPCR) was performed for HER2 mRNA on 178 formalin-fixed paraffin-embedded (FFPE) breast cancer specimens. HER2 positive, equivocal and negative cases as defined by standard criteria were included and both core biopsies and tissue sections were assessed.

resultsHER2 positive cases contained significantly higher levels of HER2 mRNA (169-1,000,000 copies/µl) by ddPCR compared with equivocal (112-139 copies/µl, p = 0.025) and negative cases (6.2-644 copies/µl. p < 0.001). A continuum of transcript quantity was observed but a cutoff of 490 copies/µl distinguished between HER2 positive and negative cases. Results were consistent between core biopsy and tissue sections.

conclusionsddPCR can be used to quantify HER2 mRNA transcripts in FFPE breast cancer specimens. Our results highlight the potential of ddPCR on FFPE tissue to be used to accurately quantify HER2 transcripts. Validation in large cohorts will be required to determine a clinically applicable cutoff.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPolymerase Chain ReactionRNA, MessengerERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNA, MessengerBreast cancerDigital droplet PCRHuman epidermal growth factor receptor

Identifiers

PMID27837339
OpenAlexW2550814237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.